Project Grant H8G48209

This $5,358,220.00 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Public Health Emergency Response: Cooperative Agreement for Emergency Response (CFDA 93.354) program will support the Hawaii Department of Health in increasing vaccination rates across the state. The award will fund the creation and maintenance of a multidisciplinary workgroup to focus vaccination education and outreach efforts on populations disproportionately affected by the...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop and test a novel stakeholder-informed intervention to improve routine vaccination of hospitalized children. The $220,000 award will fund the "Presumptively Initiating Vaccines and Optimizing Talk for Inpatients (PIVOT-IN)" intervention, which includes: 1) a standardized screening...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

This federal Project Grant award of $207,262 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on developing an mRNA vaccine against Bourbon virus, an emerging tick-borne virus that can infect and cause disease in humans. The primary objective is to evaluate the efficacy of the mRNA vaccine in a mouse model and determine its mechanism of action. A secondary objective is to test different viral antigens and...

This federal Cooperative Agreement award of $14,375,039.00 from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Non-Governmental Organization Based program (CFDA 93.939) will support the Virginia Department of Health's (VDH) Division of Disease Prevention (DDP) in implementing a comprehensive and integrated HIV surveillance and prevention program. The key objectives are to: 1) Prevent new HIV infections; 2) Improve health outcomes for people living with...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to identify factors influencing parental hesitancy towards seasonal respiratory vaccines (SRVs) for children in the post-COVID-19 pandemic era. The total funding amount is $310,644.00, with an award date of August 13, 2024 and an ultimate completion date of March 10, 2025. The key...

The U.S. Centers for Disease Control and Prevention (CDC) has awarded a $1,050,000 Cooperative Agreement under the Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program to the University of Arizona. The grant aims to enhance vaccine uptake across the lifespan through community-based participatory research in border and rural regions. Key activities include developing innovative points of access and altering social norms to improve vaccination rates. The University of...

This Project Grant award of $1,164,930 from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) will support research to examine the impact of different school-located vaccination (SLV) models on routine, influenza, and COVID-19 vaccination rates among school-aged children in Colorado, particularly for health disparity populations. The Rand Corporation, a nonprofit global policy think tank, will lead this 3-year study...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an HIV vaccine. The $228,825 award, effective August 9, 2024 through June 30, 2026, aims to synergize neutralizing and non-neutralizing antibody targets at the HIV/SIV viral spike apex. The research will 1) design and validate a vaccine immunogen focused on the V2B neutralization epitope, and 2)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $534,242.00 to the New York Blood Center, Inc. to study the immune and behavioral responses of transgender women to seasonal COVID-19 vaccines. The goal is to understand how gender-affirming hormone therapy impacts immune function and vaccine efficacy, as well as to develop an intervention to improve COVID-19 vaccine...